Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT04921345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT04921345
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Galderma R&D
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Nemolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 23, 2021
- Primary completion
- Apr 27, 2025
- Completion
- Apr 27, 2025
- Last update posted
- Jul 17, 2025
2021 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site #8636 | Fountain Valley | California | 92708-3701 | — |
| Galderma Investigational Site #9937 | San Diego | California | 92123-2746 | — |
| Galderma Investigational Site #9930 | Vista | California | 92083-6031 | — |
| Galderma Investigational Site #9929 | Coral Gables | Florida | 92083-6031 | — |
| Galderma Investigational Site #8142 | Indianapolis | Indiana | 46250-2041 | — |
| Galderma Investigational Site #8092 | Louisville | Kentucky | 40217-1444 | — |
| Galderma Investigational Site #8155 | Troy | Michigan | 48084-5260 | — |
| Galderma Investigational Site #8560 | West Bloomfield | Michigan | 48322 | — |
| Galderma Investigational Site #8242 | Brooklyn | New York | 11203-2012 | — |
| Galderma Investigational Site #9938 | New York | New York | 10032-3729 | — |
| Galderma Investigational Site #8206 | Norman | Oklahoma | 73069-6301 | — |
| Galderma Investigational Site #8255 | Philadelphia | Pennsylvania | 19103-4708 | — |
| Galderma Investigational Site #9931 | Beaumont | Texas | 77706-3061 | — |
| Galderma Investigational Site #78218-3128 | San Antonio | Texas | 78218-3128 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04921345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04921345 live on ClinicalTrials.gov.